Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
44.26
-0.45 (-1.01%)
At close: Dec 5, 2025, 4:00 PM EST
44.28
+0.02 (0.05%)
After-hours: Dec 5, 2025, 5:59 PM EST
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Marino Garcia |
Contact Details
Address: 7 Times Square, 43rd Floor New York, New York 10036 United States | |
| Phone | 929 999 4055 |
| Website | dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer and Director |
| Ryan Savitz | Chief Financial Officer and Chief Business Officer |
| Simrat Randhawa M.B.A., M.D. | Executive Vice President and Head of Research & Development |
| Edward G. Carr | Chief Accounting Officer |
| Judson Taylor | Senior Vice President and Head of Technical Operations |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations and Corporate Affairs |
| Adam M. Veness Esq. | Senior Vice President, General Counsel and Secretary |
| Kristina Maximenko | Chief People Officer |
| Rashieda Gluck | Head of Clinical Development Operations |
| Scott Nogi M.B.A. | Head of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2025 | 144 | Filing |
| Nov 25, 2025 | SCHEDULE 13D/A | Filing |
| Nov 19, 2025 | SCHEDULE 13D/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 144 | Filing |
| Nov 12, 2025 | SCHEDULE 13G | Filing |